Ascend Laboratories, LLC

FDA Regulatory Profile

Ascend Laboratories, LLC has 51 FDA recalls, 5 inspections, 0 510(k) clearances and 2 compliance actions on record.

Latest recall
D-0045-2027 · Class II · Oct 6, 2026
Latest inspection
Nov 10, 2021 · VAI

Reviewing Ascend Laboratories, LLC as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Ascend Laboratories, LLC yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls51Nov 2, 2026File dated Oct 27, 2026Current
510(k) clearances0Nov 2, 2026File dated Oct 30, 2026Current
Inspections5Nov 7, 2026Newest record Oct 28, 2026Current
Compliance actions2Nov 2, 2026Newest record Oct 29, 2026Current

Recent Recalls

NumberClassProductDate
D-0045-2027Class IIAmlodipine and Olmesartan Medoxomil Tablets, 10mg/40mg, 30 Tablets, Rx only, Manufactured by: Alkem…Oct 6, 2026
D-0737-2026Class IIIDabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx…Jul 16, 2026
D-0738-2026Class IIIDabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx…Jul 16, 2026
D-0739-2026Class IIIDabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx…Jul 16, 2026
D-0712-2026Class IIAmlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle, Rx Only…Jul 8, 2026
D-0736-2026Class IIIDabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem…Jun 30, 2026
D-0735-2026Class IIIDabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem…Jun 30, 2026
D-0597-2026Class IIMinocycline Hydrochloride Extended-Release Tablets, USP, 115 mg, 30-count bottle, Rx Only…Jun 1, 2026
D-0556-2026Class IIAmlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx Only, 30-count bottle, Manufactured by…May 5, 2026
D-0547-2026Class IIAscend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only…Apr 27, 2026
D-0019-2026Class IIAtorvastatin Calcium Tablets USP, 20 mg, Rx Only, a). 90-count(NDC 67877-512-90), b). 500-count…Sep 19, 2025
D-0020-2026Class IIAtorvastatin Calcium Tablets USP, 80 mg, Rx Only, a). 90-count(NDC 67877-514-90), b). 500-count(NDC…Sep 19, 2025
D-0017-2026Class IIAtorvastatin Calcium Tablets USP, 10 mg, Rx Only a) 90-count bottle (NDC 67877-511-90), b)…Sep 19, 2025
D-0018-2026Class IIAtorvastatin Calcium Tablets USP, 40 mg, Rx Only, a). 90-count (NDC 67877-513-90), b). 500-count…Sep 19, 2025
D-0645-2025Class IIAripiprazole Tablets, USP, 10 mg, 30-count bottles, Rx only, Manufactured by: Alken Laboratories…Aug 28, 2025
D-0576-2025Class IIAmlodipine and Olmesartan Medoxomil Tablets, 5 mg/ 40 mg, 30-count bottle, Rx Only, Manufactured by…Jul 21, 2025
D-0533-2025Class IIRizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem…Jul 9, 2025
D-0534-2025Class IIRizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by…Jul 9, 2025
D-0469-2025Class IICephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed), Rx Only, Manufactured by…May 23, 2025
D-0468-2025Class IICephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by…May 23, 2025

Recent FDA Inspections

DateSiteProductClassificationFEI
Nov 10, 2021Bedminster, NJDrugsVoluntary Action Indicated (VAI)3004459274
Jun 24, 2021Bedminster, NJDrugsVoluntary Action Indicated (VAI)3004459274
Jul 6, 2017Bedminster, NJDrugsNo Action Indicated (NAI)3004459274
Dec 11, 2013Bedminster, NJDrugsOfficial Action Indicated (OAI)3004459274
Feb 10, 2011Bedminster, NJDrugsNo Action Indicated (NAI)3004459274

NAI means no objectionable conditions or practices were found during the inspection. VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. OAI means regulatory and/or administrative actions are recommended.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.